Caffeine citrate therapy for apnea of prematurity

Neonatal Network

Volumn 30, Issue 6, 2011, Pages 408-412

  Johnson, Patricia J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CAFFEINE CITRATE; CENTRAL STIMULANT AGENT; CITRIC ACID;

APNEA; DOSE RESPONSE; DRUG ADMINISTRATION; HUMAN; NEWBORN; PREMATURITY; REVIEW;

APNEA; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CITRATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES;

EID: 84861813689     PISSN: 07300832     EISSN: 15392880     Source Type: Journal    
DOI: 10.1891/0730-0832.30.6.408     Document Type: Article

References (42)

1. Henderson-Smart, D. J., & Davis, P. G. (2003). Prophylactic methylxanthines for extubation in preterm infants. Cochrane Database of Systemic Reviews, (1), CD000139.
2. Steer, P., Flenady, V., Shearman, A., Charles, B., Gray, P. H., Henderson-Smart, D., . . . Walsh, A. (2004). High dose caffeine citrate for extubation of preterm infants: A randomised controlled trial. Archives of Diseases in Childhood. Fetal and Neonatal Edition, 89(6), F499-F503.
3. Poets, C. F. (2008). Apnea of prematurity, sudden infant death syndrome, and apparent life-threatening events. In L. M. Taussig & L. I. Landau (Eds.), Pediatric respiratory medicine (pp. 413-434). Philadelphia, PA: Mosby.
4. Poets, C. F. (2010). Interventions for apnoea of prematurity: A personal view. Acta Paediatrica, 99(2), 172-177.
5. Aranda, J. V., & Turmen, T. (1979). Methylxanthines in apnea of prematurity. Clinics in Perinatology, 6(1), 87-108.
6. Barrington, K., & Finer, N. (1991). The natural history of the appearance of apnea of prematurity. Pediatric Research, 29(4 Pt. 1), 372-375.
7. Erenberg, A., Leff, R. D., Haack, D. G., Mosdell, K. W., Hicks, G. M., & Wynne, B. A. (2000). Caffeine citrate for the treatment of apnea of prematurity: A double-blind, placebo-controlled study. Pharmacotherapy, 20(6), 644-652.
8. Henderson-Smart, D. J., & Steer, P. A. (2010). Caffeine versus theophylline for apnea in preterm infants. Cochrane Database of Systematic Reviews, 20(1), CD000273.
9. Henderson-Smart, D. J. (1981). The effect of gestational age on the incidence and duration of recurrent apnoea in newborn babies. Australian Paediatric Journal, 17(4), 273-276.
10. Scanlon, J. E., Chin, K. C., Morgan M. E., Durbin, G. M., Hale, K. A., & Brown, S. S. (1992). Caffeine or theophylline for neonatal apnoea? Archives of Disease in Childhood, 67(4 Spec. No.), 425-428.
11. Comer, A. M., Perry, C. M., & Figgitt, D. P. (2001). Caffeine citrate: A review of its use in apnoea of prematurity. Paediatric Drugs, 3(1), 61-79.
12. Kuzemko, J. A. (2003). Historical perspectives: Use of methylxanthines in the management of apneic attacks in the newborn. Neo Reviews, 4(3), e62-e64. Retrieved from http://neoreviews.aappublications.org
13. Kuzemko, J. A., & Paala, J. (1973). Apnoeic attacks in the newborn treated with aminophylline. Archives of Disease in Childhood, 48(5), 404-406.
14. Henderson-Smart, D. J., & Steer, P. (2001). Methylxanthine treatment for apnea in preterm infants. Cochrane Database Systematic Reviews, (3), CD000140.
15. Marchal, F., Bairam, A., & Vert, P. (1987). Neonatal apnea and apneic syndromes. Clinics in Perinatology, 14(3), 509-529.
16. U.S. Food and Drug Administration. (2005). Drug approval package. Retrieved from http://www.accessdata.fda.gov/Scripts/cder/Drugsat FDA/index.cfm?fuseaction5Search.Label-ApprovalHistory#apphist; http://www.accessdata.fda.gov/drugsatfda-docs/nda/99/020793 -000-Cafcit®TOC. cfm
17. Davis, P. G., Schmidt, B., Roberts, R. S., Doyle, L. W., Asztalos, E., Haslam, R., . . . Tin, W. (2010). Caffeine for Apnea of Prematurity trial: Benefits may vary in subgroups. The Journal of Pediatrics, 156(3), 382-387.
18. Buck, M. L., Hofer, K. N., & McCarthy, M. W. (2008). Caffeine citrate for the treatment of apnea of prematurity: Dosing recommendations. Pediatric Pharmacology, 14(6), 1-4. Retrieved from http://www.medscape.com
19. Page, C. P. (1999). Recent advances in our understanding of the use of theophylline in the treatment of asthma. Journal of Clinical Pharmacology, 39(3), 237-240.
20. Bancalari, E. (2006). Caffeine for apnea of prematurity. New England Journal of Medicine, 345(20), 2179-2181.
21. Martin, R. J., Miller, M. J., & Carlo, W. A. (1986). Pathogenesis of apnea in preterm infants. The Journal of Pediatrics, 109(5), 733-741.
22. Herlenius, E., & Lagercrantz, H. (1999). Adenosinergic modulation of respiratory neurones in the neonatal rat brainstem in vitro. The Journal of Physiology, 518(Pt. 1), 159-172.
23. Wilson, C. G., Martin, R. J., Jaber, M., Abu-Shaweesh, J., Jafri, A., Haxhiu, M. A., & Zaidi, S. (2004). Adenosine 2A2 receptors interact with GAB Aergic pathways to modulate respiration in neonatal piglets. Respiratory Physiology & Neurobiology, 141(2), 201-211.
24. Natarajan, G., Lulic-Botica, M., & Aranda, J. V. (2007). Pharmacology review: Clinical pharmacology of caffeine in the newborn. NeoReviews, 8(5), e214-e221. Retrieved from http://neoreviews.aappublications. org/cgi/content/abstract/neoreviews;8/5/e214
25. Sui, A., & James, A. (2010). Apnea of prematurity pharmacotherapy. US Pharmacist, 35(3), HS2-HS6. Retrieved from http://www.medscape.com
26. Aranda, J. V., Cook, C. E., Gorman, W., Collinge, J. M., Loughnan, P. M., Outerbridge, E. W., . . . Neims, A. H. (1979). Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. The Journal of Pediatrics, 94(4), 663-668.
27. Giacoia, G. P., Jungbluth, G. L., & Jusko, W. J. (1989). Effect of formula feeding on oral absorption of caffeine in premature infants. Developmental Pharmacology and Therapeutics, 12(4), 205-210.
28. Mead Johnson and Co. (2003). Cafcit® (caffeine citrate) injection and oral solution prescribing information. Retrieved from http://www.bedfordlabs. com
29. al-Alaiyan, S., al-Rawithi, S., Raines, D., Yusuf, A., Legayada, E., Shoukri, M. M., & el-Yazigi, A. (2001). Caffeine metabolism in premature infants. Journal of Clinical Pharmacology, 41(6), 620-627.
30. Davis, J. M., Spitzer, A. R., Stefano, J. L., Bhutani, V., & Fox, W. W. (1987). Use of caffeine in infants unresponsive to theophylline in apnea of prematurity. Pediatric Pulmonology, 3(2), 90-93.
31. Le Guennec, J. C., Billon, B., & Paré C. (1985). Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: Influence of gestational age, hepatic disease, and breast-feeding. Pediatrics, 76(5), 834-840.
32. Arnaud, M. J. (1987). The pharmacology of caffeine. Progress in Drug Research, 31, 273-313.
33. Lee, T. C., Charles, B., Steer, P., Flenady, V., & Shearman, A. (1997). Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clinical Pharmacology & Therapeutics, 61(6), 628-640.
34. Falcão, A. C., Fernández de Gatta, M. M., Delgado Iribarnegaray, M. F., Santos Buelga, D., García, M. J., Dominguez-Gil, A., & Lanao, J. M. (1997). Population pharmacokinetics of caffeine in premature neonates. European Journal of Clinical Pharmacology, 52(3), 211-217.
35. Young, T. E., & Magnum, B. (2010). Caffeine citrate. In Neofax: A manual of drugs used in neonatal care (23rd ed., pp. 272-273). Montvale, NJ: Thomson Reuters.
36. Hoecker, C., Nelle, M., Poeschl, J., Beedgen, B., & Linderkamp, O. (2002). Caffeine impairs cerebral and intestinal blood flow velocity in preterm infants. Pediatrics, 109(5), 784-787.
37. Hoecker, C., Nelle, M., Beedgen, B., Rengelshausen, J., & Linderkamp, O. (2006). Effects of a divided high loading dose of caffeine on circulatory variables in preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition, 91(1), F61-F64.
38. Schmidt, B., Roberts, R. S., Davis, P., Doyle, L. W., Barrington, K. J., Ohlsson, A., . . . Tin, W. (2007). Long-term effects of caffeine therapy for apnea of prematurity. The New England Journal of Medicine, 357(19), 1893-1902.
39. Anderson, B. J., Gunn, T. R., Holford, N. H., & Johnson, R. (1999). Caffeine overdose in a premature infant: Clinical course and pharmacokinetics. Anaesthesia and Intensive Care, 27(3), 307-311.
40. Natarajan, G., Botica, M. L., Thomas, R., & Aranda, J. V. (2007). Therapeutic drug monitoring for caffeine in preterm neonates: An unnecessary exercise? Pediatrics, 119(5), 936-940.
41. Schmidt, B., Roberts, R. S., Davis, P., Doyle, L. W., Barrington, K. J., Ohlsson, A., . . . Tin, W. (2006). Caffeine therapy for apnea of prematurity. The New England Journal of Medicine, 354(20), 2112-2121.
42. Stevenson, D. K. (2007). On the caffeination of prematurity. The New England Journal of Medicine, 357(19), 1967-1968.